11 research outputs found
Attribution of Arctic Sea Ice Decline from 1953 to 2012 to Influences from Natural, Greenhouse Gas, and Anthropogenic Aerosol Forcing
Selective Oxidation of Chromium by O2 Impurities in CO2 During Initial Stages of Oxidation
Human T-lymphotropic virus type 1 infection and disease in Spain
Human T-lymphotropic virus type 1 (HTLV-1) infection is a neglected disease despite roughly 15 million people are chronically infected worldwide. Lifelong less than 10% of carriers develop life-threatening diseases, mostly a subacute myelopathy known as tropical spastic paraparesis (TSP) and a lymphoproliferative disorder named adult T-cell leukemia (ATL). HTLV-1 is efficiently transmitted perinatally (breastfeeding), sexually (more from men to women) and parenterally (transfusions, injection drug user (IDU), and transplants). To date there is neither prophylactic vaccine nor effective antiviral therapy. A total of 327 cases of HTLV-1 infection had been reported at the HTLV-1 Spanish registry until December 2016, of whom 34 had been diagnosed with TSP and 25 with ATL. Overall 62% were Latin American immigrants and 13% were persons of African origin. The incidence of HTLV-1 in Spain has remained stable for nearly a decade with 20–25 new cases yearly. Of the 21 newly diagnosed HTLV-1 cases during year 2016, one was a native Spaniard pregnant woman, and four presented with symptomatic disease, including three with ATL and one with TSP. Underdiagnosis of HTLV-1 in Spain must be high (iceberg model), which may account for the disproportionate high rate of symptomatic cases (almost 20%) and the late recognition of preventable HTLV-1 transmissions in special populations, such as newborns and transplant recipients. Our current estimate is of 10 000 persons living with HTLV-1 infection in Spain. Given the large flux of immigrants and visitors from HTLV-1 endemic regions to Spain, the expansion of HTLV-1 screening policies is warranted. At this time, it seems worth recommending HTLV testing to all donor/recipient organ transplants and pregnant women regardless place of birth. Although current leukoreduction procedures largely prevent HTLV-1 transmission by blood transfusions, HTLV testing of all first-time donors should be cost-effective contributing to unveil asymptomatic unaware HTLV-1 carriers.The work was funded in part by grants from F-IES and ISCIII-Fondos Feder (PI13/01574; ICI14/00372; CD14/0243; FI14/0264; CM13/0309; CES12/003).Peer reviewe
Atom probe study of impurity segregation at grain boundaries in chromia scales grown in CO2 gas
Mechanisms of Oxide Scale Formation on Ferritic Interconnect Steel in Simulated Low and High pO2 Service Environments of Solid Oxide Fuel Cells
Screening for HTLV-1 infection should be expanded in Europe
Human T-cell lymphotropic virus type 1 (HTLV-1) infection is spreading globally at an uncertain speed. Sexual, mother-to-child, and parenteral exposure are the major transmission routes. Neither vaccines nor antivirals have been developed to confront HTLV-1, despite infecting over 10 million people globally and causing life-threatening illnesses in 10% of carriers. It is time to place this long-neglected disease firmly into the 2030 elimination agenda. Current evidence supports once-in-life testing for HTLV-1, as recommended for HIV, hepatitis B and C, along with targeted screening of pregnant women, blood donors, and people who attended clinics for sexually transmitted infections (STIs). Similar targeted screening strategies are already being performed for Chagas disease in some Western countries in persons from Latin America. Given the high risk of rapid-onset HTLV-1-associated myelopathy, universal screening of solid organ donors is warranted. To minimize organ wastage, however, the specificity of HTLV screening tests must be improved. HTLV screening of organ donors in Europe has become mandatory in Spain and the United Kingdom. The advent of HTLV point-of-care kits would facilitate testing. Finally, increasing awareness of HTLV-1 will help those living with HTLV-1 to be tested, clinically monitored, and informed about transmission-preventive measures
The Burden of Neglected HIV-2 and HTLV-1 Infections in Spain.
HIV-2 and HTLV-1 infections are globally less frequent than those produced by HIV-1, the classical AIDS
agent. In Spain and up to the end of 2014, a total of 310 cases of HIV-2, 274 of HTLV-1, and 776 of HTLV-2
infections had been reported. No cases of HTLV-3 or HTLV-4 infections have been identified so far in Spain.
Most persons infected with HIV-2 or HTLV-1 acknowledge epidemiological risk factors for contagion, such
as originating from or living in endemic regions and/or having had sexual partners from those areas. However,
risk factors could not be recognized in up to 20-25% of carriers in Spain. Thus, it seems worth keeping a
high level of clinical suspicion in order to identify earlier these neglected human retroviral infections, since
diagnostic procedures and antiviral treatment are specific for each of these agents. In this article we
summarize the major contributions reported at the meeting of the Spanish Group for HIV-2/HTLV held in
Madrid in December 201